{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:01:27Z","timestamp":1790744487784,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    We present the case of a 13-year-old boy with refractory systemic lupus erythematosus (SLE) who achieved drug-free remission after anti-CD19 CAR-T cell therapy, but subsequently experienced Epstein\u2013Barr virus (EBV) reactivation on day 142 after CAR T-cell infusion and peak EBV load was 24,400 IU\/mL with a severe drop in platelets to 8\u00d710\n                    <jats:sup>9<\/jats:sup>\n                    \/L, which leading to relapse of SLE and manifestations of chronic active EBV disease (CAEBVD). The whole exogenous gene testing found X chromosome Xp22.33q28 region (chrX: 200855-155239820) a duplicate of about 155.04Mbp,which is associated with the development of Klinefelter syndrome (KS).The temporal association between EBV resurgence and SLE flare suggests that CAR-T-induced immunosuppression with some genetic background may permit EBV reactivation, which can be associated with the return of autoimmunity. This case highlights the need for vigilant monitoring for opportunistic infections and genetic background, particularly EBV, after CAR-T therapy for autoimmune diseases, as they may contribute to disease relapse.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1956166","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:51:53Z","timestamp":1790743913000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Relapse of SLE associated with EBV infection in a patient after CAR-T cell therapy: a clinical case"],"prefix":"10.3389","volume":"17","author":[{"given":"Ping","family":"Zeng","sequence":"first","affiliation":[{"name":"Zunyi Medical University","place":["Zunyi, Guizhou, China"]},{"name":"Department of Pediatric, Allergy Immune & Rheumatology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University Guangdong Provincial Clinical Research Center for Child Health","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Allergy Immune & Rheumatology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University Guangdong Provincial Clinical Research Center for Child Health","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Allergy Immune & Rheumatology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University Guangdong Provincial Clinical Research Center for Child Health","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xian","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Allergy Immune & Rheumatology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University Guangdong Provincial Clinical Research Center for Child Health","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Immunology, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Allergy Immune & Rheumatology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University Guangdong Provincial Clinical Research Center for Child Health","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Allergy Immune & Rheumatology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University Guangdong Provincial Clinical Research Center for Child Health","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Allergy Immune & Rheumatology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University Guangdong Provincial Clinical Research Center for Child Health","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Allergy Immune & Rheumatology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University Guangdong Provincial Clinical Research Center for Child Health","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.2017.71s1-po4123","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s40001-025-02694-1","article-title":"The PD-1\/PD-L1 pathway and Epstein\u2013Barr virus","volume":"30","author":"Wu","year":"2025","journal-title":"Eur J Med Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01181-y","article-title":"Epstein-Barr virus pathogenesis and emerging control strategies","volume":"23","author":"M\u00fcnz","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1200\/jco.2025.43.16_suppl.6025","article-title":"Using longitudinal spatial-omics to demonstrate in-situ Epstein-Barr virus reduction in responders to immunotherapy treated nasopharyngeal cancer","volume":"43","author":"Wu","year":"2025","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ady0210","article-title":"Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus","volume":"17","author":"Younis","year":"2025","journal-title":"Sci Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100117","article-title":"Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus","volume":"4","author":"Wood","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320940029","article-title":"Epstein-Barr virus, cytomegalovirus and BK polyomavirus burden in juvenile systemic lupus erythematosus: correlation with clinical and laboratory indices of disease activity","volume":"29","author":"Aygun","year":"2020","journal-title":"Lupus"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2741\/mcclain","article-title":"The role of Epstein-Barr virus in systemic lupus erythematosus","volume":"6","author":"McClain","year":"2001","journal-title":"Front Bioscience: A J Virtual Library"},{"key":"B10","doi-asserted-by":"publisher","first-page":"20236","DOI":"10.1038\/s41598-024-70913-6","article-title":"Gene profiling of Epstein-Barr Virus and human endogenous retrovirus in peripheral blood mononuclear cells of SLE patients: immune response implications","volume":"14","author":"Lemus","year":"2024","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10238-018-0535-0","article-title":"The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis","volume":"19","author":"Li","year":"2019","journal-title":"Clin Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1307589","article-title":"Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus","volume":"14","author":"Banko","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076156","article-title":"Epstein\u2013Barr virus reactivation as a new predictor of achieving remission or lupus low disease activity state in patients with systemic lupus erythematosus with cutaneous involvement","volume":"24","author":"Miskovic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152786","article-title":"CAR T-cell therapy in SLE: a systematic review","volume":"74","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100749","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"6","author":"Wang","year":"2025","journal-title":"Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630569","article-title":"CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11614","article-title":"Journal club: Anti-CD19 chimeric antigen receptor T cell therapy for refractory systemic lupus erythematosus","volume":"5","author":"Boulougoura","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578314","article-title":"EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance","volume":"389","author":"Serafini","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12943-025-02448-x","article-title":"The immune microenvironment of pathogen-associated cancers and current clinical therapeutics","volume":"24","author":"Wei","year":"2025","journal-title":"Mol Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104164","article-title":"Corrigendum to \"Epstein-barr virus-encoded latent membrane protein 2A promotes immune escape by upregulating SYK\/nuclear factor-\u03baB signaling in diffuse large B-cell lymphoma\" [Laboratory investigation 105 (2025) 104104","volume":"105","author":"Jiang","year":"2025","journal-title":"Lab Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.162922","article-title":"A case report of Klinefelter syndrome with schizophrenia-like psychosis and seizure disorder","volume":"37","author":"Jayaraman","year":"2015","journal-title":"Indian J Psychol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.164373","article-title":"Acne in Klinefelter syndrome-46XY\/47XXY mosaicism","volume":"60","author":"Lakshmi","year":"2015","journal-title":"Indian J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-025-10923-7","article-title":"Validation of BCMA-CD19 compound CAR-T therapy in SLE overlap syndrome: over 1.5-year follow-up","volume":"21","author":"Wang","year":"2025","journal-title":"Stem Cell Rev Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-023-1032-8","article-title":"EBV-associated lymphoproliferative disease post-CAR-T cell therapy","volume":"18","author":"Zhang","year":"2024","journal-title":"Front Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000001066","article-title":"Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections","volume":"37","author":"Kampouri","year":"2024","journal-title":"Curr Opin Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood-2025-646","article-title":"Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia","volume":"146","author":"Cain","year":"2026","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2380","article-title":"Safety and preliminary efficacy of anti-CD19 CAR T cells zorpocabtagene-autoleucel in systemic autoimmune diseases: final analysis of the castle trial","volume":"146","author":"M\u00fcller","year":"2026","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.021","article-title":"Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality","volume":"155","author":"Sutherland","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"749\u201358","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR-T cell therapy and infection: a review","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev Anti-Infe"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071684","article-title":"Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00262-025-03998-1","article-title":"Infectious complications distribution following CLL1 CAR-T cell therapy for acute myeloid leukemiass","volume":"74","author":"Xu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203133","article-title":"Predicting risk of infection in patients receiving CAR-T for aggressive lymphoma: a study exploring the utility of immune profiling","volume":"144","author":"Reynolds","year":"2026","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.849120","article-title":"Association of viral infection with the development and pathogenesis of systemic lupus erythematosus","volume":"9","author":"Iwata","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0380-5","article-title":"Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas","volume":"33","author":"Kataoka","year":"2019","journal-title":"Leukemia"},{"key":"B43","article-title":"PD1\/PD-L1 expressions in plasmablastic lymphoma with clinicopathological correlation","volume":"51","author":"Rosado","year":"2021","journal-title":"Ann Clin Lab Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536375123","article-title":"MiR-155-driven loss of ICOSL and SOCS1 in EBV+ gastric cancers renders abundant cytotoxic T cells ineffective, enabling immune evasion","volume":"123","author":"Nuovo","year":"2026","journal-title":"P Natl Acad Sci USA"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-03965-7","article-title":"DLI-induced remission in recurrent EBV-associated T\/NK-cell lymphoproliferative disease following HSCT: a case report","volume":"121","author":"Nagata","year":"2025","journal-title":"Int J Hematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"45250","DOI":"10.1038\/s41598-025-29456-7","article-title":"Latent EBV reactivation drives aberrant B-cell proliferation during ex vivo tumor-infiltrating lymphocyte expansion from EBV-negative rectal cancer tumor tissue","volume":"15","author":"Petrova","year":"2025","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e3181fe363b","article-title":"Primary cutaneous, composite, Epstein-Barr virus-associated, diffuse large B-cell lymphoma and peripheral T-cell lymphoma","volume":"33","author":"Papalas","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12974-018-1330-2","article-title":"The IFN-\u03b3\/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1\/PD-L1 therapy","volume":"15","author":"Qian","year":"2018","journal-title":"J Neuroinflamm"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e003503","DOI":"10.1136\/rmdopen-2023-003503","article-title":"PD-1\/PD-L1 governed cross-talk of exhausted CD8+ T and memory B cells in systemic lupus erythematosus","volume":"10","author":"Wang","year":"2024","journal-title":"RMD Open"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.037","article-title":"Lymphocytes in patients with chronic active Epstein-Barr virus disease exhibited elevated PD-1\/PD-L1 expression and a prevailing Th2 immune response","volume":"16","author":"Sun","year":"2024","journal-title":"Mediterr J Hematol I"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S593133","article-title":"ATG plus post-transplantation cyclophosphamide improves EBV-DNA clearance and GVHD in patients of adult chronic active Epstein-Barr virus disease undergoing allogeneic HSCT","volume":"17","author":"Liu","year":"2026","journal-title":"J Blood Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-77586","article-title":"Different graft-vs-host disease prophylaxis strategy for allogeneic hematopoietic stem cell transplantation in adults with chronic active EBV infection","volume":"146","author":"Liu","year":"2025","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad131","article-title":"Chronic active Epstein-Barr virus (EBV) infection controlled by allogeneic stem cell transplantation and EBV-specific T cells","volume":"76","author":"Meedt","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.19723\/j.issn.1671-167X.2024.06.029","article-title":"Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy","volume":"56","author":"Wang","year":"2024","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103489","article-title":"Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study","volume":"157","author":"Wang","year":"2025","journal-title":"J Autoimmun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1645304","article-title":"Case report: Remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1956166\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:52:18Z","timestamp":1790743938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1956166\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1956166"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1956166","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1956166"}}